CEYDA ORS: Open Payments
NPI 1497288625 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,587 in 76 payments from 15 companies in 2025. Trend: 2023 $774 · 2024 $2,352 · 2025 $1,587
Food & beverage: $1,504Education: $83
| Company | Payments | Amount |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | 15 | $375 |
| PFIZER INC. | 9 | $297 |
| LEO Pharma Inc. | 14 | $230 |
| GENZYME CORPORATION | 9 | $184 |
| Arcutis Biotherapeutics, Inc. | 11 | $138 |
| Almirall LLC | 3 | $71 |
| Organon LLC | 3 | $54 |
| Medimetriks Pharmaceuticals, Inc. | 3 | $47 |
| Galderma Laboratories, L.P. | 2 | $38 |
| Novartis Pharmaceuticals Corporation | 1 | $32 |
Products named: DUPIXENT, ADBRY, CIBINQO, ILUMYA, Zoryve, LITFULO, Winlevi, Seysara.
Industry payments across TX — which companies pay providers there.
